II. Indications
- Metastatic Breast Cancer (refractory)
- Metastatic Liposarcoma (refractory, non-resectable)
III. Mechanism
- See Mitotic Inhibitor Chemotherapy
- Eribulin is a Halichondrin B analog with antineoplastic properties
- Dervied from the marine sponge Lissodendoryx.
- Eribulin is an anti-tubulin agent
- Binds to tubulin (at vinca doman)
- Inhibits tubulin polymerization and microtubule assembly
- Arrests cell cycle at G2/M phase
IV. Medications
- Eribulin 1 mg/2ml intravenous solution
V. Dosing
- See other references for disease specific dosing protocols
- Adjust dosing in renal and hepatic Impairment
- Adults: 1.4 mg/m2 on days 1 and 8, in every 21 day cycles
VI. Adverse Effects
VII. Pharmacokinetics
- Hepatic excretion in feces unchanged
VIII. Safety
- Avoid in Lactation
- Avoid in pregnancy (all trimesters)
- Use reliable Contraception
IX. Resources
- Eribulin Injection Solution (DailyMed)